DASSAULT SYSTEMES | LIFE SCIENCES



CAR-T THERAPY IS SET TO REVOLUTIONIZE BLOOD CANCER TREATMENT

Learn how a large biotech company leveraged solutions from Dassault Systèmes to accelerate their fight against cancer.

ABOUT THE CUSTOMER:

A top 20 Biotech company researching and developing immunotherapies to exploit the body's immune system to fight cancers, infectious diseases and other serious conditions. One of their many products currently in development is in CAR-T therapy, which is a new and expanding treatment option for blood cancers.

This customer has worked with Dassault Systèmes Life Sciences brands, including solutions from Medidata AI and BIOVIA.

KEY TAKEAWAYS:

Leveraged solutions across the Dassault Systèmes portfolio to:

- Standardize data capture that supported rapid expansion of their R&D organization across global sites in pre-trial workflows.
- Refine their trial protocol to reduce the number of ICANS or CRS events that occurred in patients.
- Identify the most optimal treatment patterns in relation to each patients' clinical outcome.
- Adequately refine their inclusion and exclusion criteria in order to better understand dosing schedule and effects.

THE CHALLENGE

While CAR-T therapies are starting to offer hope for some of the most aggressive forms of cancer, there have been a few common roadblocks in the development of this promising, new therapy. These challenges include life-threatening adverse events (AEs), complexity of pre-conditioning regimens, dosing, manufacturing, patient selection and more.

THE SOLUTION

This biotech company used BIOVIA ONE Lab during the pre-clinical phase to rapidly scale workflows across globally dispersed sites, allowing for appropriate site-level data capture configurations while ensuring that procedures and data were standardized and easily accessible. Accelerating their development of their life-changing therapy.

To build a safer, more effective trial protocol for patients enrolling in the clinical trial, the R&D team leveraged a high fidelity synthetic data clinical trial data, generated from a base cross-sponsor dataset of over 3,000 NHL, ALL, and solid tumor patients treated with CD19 Auto CAR-Ts and Bispecifics. By leveraging this dataset, the biotech to analyze treatment-emergent adverse events. Ultimately, the insights provided greatly increased the probability of technical and regulatory success for the biotech's CAR-T development program.

Our **3D**EXPERIENCE® platform powers our brand applications, serving 12 industries, and provides a rich portfolio of industry solution experiences.

Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our **3D**EXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable.The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all – consumers, patients and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit **www.3ds.com**.

Europe/Middle East/Africa
Dassault Systèmes
10, rue Marcel Dassault
CS 40501
78946 Vélizy-Villacoublay Cedex
France

Asia-Pacific
Dassault Systèmes
17F, Foxconn Building,
No. 1366, Lujiazui Ring Road
Pilot Free Trade Zone, Shanghai 200120
China

Americas
Dassault Systèmes
175 Wyman Street
Waltham, Massachusetts
02451-1223
USA